- SG$1.88bn
- SG$1.75bn
- SG$706.92m
- 68
- 46
- 53
- 59
Annual income statement for Raffles Medical, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 522 | 568 | 724 | 823 | 707 |
| Cost of Revenue | |||||
| Gross Profit | 411 | 432 | 581 | 731 | 616 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 446 | 480 | 602 | 627 | 591 |
| Operating Profit | 76.2 | 88.4 | 121 | 195 | 116 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 75.9 | 84.4 | 116 | 191 | 119 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 60.5 | 64.7 | 83.7 | 143 | 91.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 60.3 | 65.9 | 84.2 | 143 | 90.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 60.3 | 65.9 | 84.2 | 143 | 90.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.033 | 0.038 | 0.044 | 0.082 | 0.045 |
| Dividends per Share | |||||
| Special Dividends per Share |